AMAG Pharmaceuticals prices public offering of common stock

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share.

The number of shares reflects an increase of 600,000 shares over the number of shares anticipated to be sold as previously announced. AMAG Pharmaceuticals also granted the underwriters an over-allotment option for an additional 540,000 shares. All of the shares are being offered by AMAG Pharmaceuticals. The offering is expected to close on or about January 26, 2010, subject to customary closing conditions.

Morgan Stanley & Co. Incorporated, J.P. Morgan Securities Inc. and Goldman, Sachs & Co. are acting as the joint book-running managers for the offering. Leerink Swann, LLC, Canaccord Adams, Inc. and Robert W. Baird & Co. are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective upon filing. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus may be obtained from Morgan Stanley & Co. Incorporated at 180 Varick Street, New York, New York 10014, Attention: Prospectus Department, or by telephone at 866-718-1649 or by email at [email protected]; from J.P. Morgan Securities Inc., Attention: Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204; or from Goldman, Sachs & Co. Attention: Prospectus Department, 85 Broad Street, New York, New York 10004, or by telephone at 1-866-471-2526, by fax at 212-902-9316 or by email at [email protected].